Related Experiment Videos
Silent myocardial ischaemia in the elderly
1Department of Medicine, VA Central California Healthcare System/UCSF Program, Fresno, California 93703,USA. deed@ucsfresno.edu
Insights
Silent myocardial ischemia (SMI) is common in elderly patients with coronary artery disease (CAD), often remaining undetected. Beta-blockers are a preferred treatment, but long-term benefits require further study.
Area of Science:
- Cardiology
- Geriatric Medicine
- Internal Medicine
Background:
- Coronary artery disease (CAD) is a major cause of mortality and morbidity in the elderly population.
- Silent myocardial ischemia (SMI) is a frequent, often asymptomatic, presentation of CAD in older adults.
- SMI can be present in up to 40% of elderly patients without a prior CAD diagnosis and 50% with known CAD.
Purpose of the Study:
- To highlight the prevalence and diagnostic challenges of silent myocardial ischemia (SMI) in the elderly.
- To review current therapeutic strategies for SMI in this demographic.
- To identify gaps in knowledge regarding the long-term benefits of SMI treatment in older adults.
Main Methods:
- Review of recent studies on silent myocardial ischemia in elderly patients.
- Discussion of diagnostic methods, including ambulatory 24- to 48-hour Holter monitoring.
- Evaluation of anti-ischaemic drug efficacy for SMI management.
Main Results:
- Silent myocardial ischemia is a common finding in elderly patients, even those on antianginal therapy.
- Ambulatory Holter monitoring is essential for diagnosing residual SMI during daily activities.
- Beta-blockers, alone or in combination with nitrates or calcium antagonists, appear to be the most effective treatment for SMI.
Conclusions:
- Silent myocardial ischemia is a significant clinical issue in the elderly population.
- Effective diagnosis and management of SMI are crucial, despite the absence of typical anginal symptoms.
- Further research is needed to establish the long-term clinical benefits of treating SMI in elderly individuals.
Abstract:
Coronary artery disease (CAD) is a leading cause of death and disability in the elderly. Several recent studies have shown that silent myocardial ischaemia (SMI) is a common manifestation of CAD, especially in the elderly. As many as 40% of elderly patients with no prior history of CAD may have underlying asymptomatic disease and up to 50% of elderly patients with known CAD might have evidence of SMI. The results of studies in elderly patients with CAD have also shown that SMI might exist despite antianginal therapy that is considered adequate for symptom control. In order to diagnose such residual SMI, the clinician would need to perform 24- to 48-hour Holter monitoring in the ambulatory setting while the patient is performing routine daily activities. Although a number of anti-ischaemic drugs have been evaluated for the treatment of SMI, available data suggest that beta-blocker given alone or in combination with a nitrate compound or calcium antagonist provides the best therapeutic choice. The long term benefit of SMI suppression in elderly patients has not been established. Future studies need to evaluate the clinical benefits of therapy given for SMI in the elderly.